clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00026364 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
P17 | country | United States of America | Q30 |
P582 | end time | 2006-12-01 | |
P921 | main subject | rectum adenocarcinoma | Q18554959 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 22 | |
P4844 | research intervention | calcium oxalate | Q412399 |
leucovorin calcium | Q27077063 | ||
fluorouracil | Q238512 | ||
irinotecan | Q412197 | ||
P6153 | research site | Dana–Farber Cancer Institute | Q1159198 |
P580 | start time | 2001-11-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer |
Search more.